Market-Moving News for July 22nd
Company | Date | Price Target | Rating | Analyst |
---|---|---|---|---|
2/28/2022 | $3.50 | Overweight | Cantor Fitzgerald |
MIAMI, FL / ACCESSWIRE / September 11, 2024 / MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA), a preclinical-stage pharmaceutical company focused on developing innovative therapies for neurologic and neuropsychiatric disorders, announced today that it has selected neuropathic pain as the initial and primary indication for its novel oral ketamine analog, Ketamir-2. The company has submitted a request for a pre-Investigational New Drug (IND) meeting with the U.S. Food and Drug Administration (FDA) and anticipates the meeting to occur in November 2024. All ongoing regulatory IND-enabling studies are advancing smoothly, and MIRA remains on track to submit its IND to the FDA by the end of this year, wit
KIRYAT ONO, ISRAEL and EDISON, N.J., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Pharma Two B Ltd. ("Pharma Two B"), a late-clinical stage company that is developing P2B001, an innovative combination product candidate for the treatment of Parkinson's Disease ("PD") and Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA) ("Hepion"), a clinical stage biopharmaceutical company that has been developing a treatment for non-alcoholic steatohepatitis ("NASH"), hepatocellular carcinoma ("HCC"), and other chronic liver diseases, today jointly announced the filing of a registration statement of Pharma Two B on Form F-4 (the "Registration Statement") with the U.S. Securities and Exchange Commission (the "SEC"). The
LAS VEGAS, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Richtech Robotics Inc. (NASDAQ:RR), ("Richtech Robotics" or the "Company"), a Nevada-based provider of AI-driven service robots, today announced the closing of its previously announced public offering of an aggregate of 15,555,557 shares of its Class B common stock (or Class B common stock equivalents in lieu thereof) and warrants to purchase up to 15,555,557 shares of Class B common stock (the "Warrants"), at a combined public offering price of $1.35 per share (or per Class B common stock equivalent in lieu thereof) and accompanying Warrant. The Warrants have an exercise price of $1.35 per share, are exercisable immediately upon issuance and e
Latest positive preclinical data provides another step in the path to potential IND submission this year for novel ketamine analog.
Richtech Robotics's (NYSE:RR) short percent of float has fallen 23.28% since its last report. The company recently reported that it has 411 thousand shares sold short, which is 1.78% of all regular shares that are available for trading. Based on its trading volume, it would take traders 3.01 days to cover their short positions on average. Why Short Interest Matters Short interest is the number of shares that have been sold short but have not yet been covered or closed out. Short selling is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises. Short inter
Shares of Comcast Corporation (NASDAQ:CMCSA) fell sharply during Tuesday's session after the company reported worse-than-expected second-quarter sales results. Comcast reported second-quarter revenue decline of 2.7% year-over-year to $29.69 billion, missing the analyst consensus estimate of $30.02 billion.The company reported adjusted EPS of $1.21, beating analyst consensus estimates of $1.12, according to data from Benzinga Pro. Comcast shares declined 6.1% to $37.12 on Tuesday. Here are some other stocks moving in today’s mid-day session. Gainers Azitra, Inc. (NYSE:AZTR) shares jumped 529% to $10.19 after the company announced that the U.S. Patent and Trademark Office grant
SC 13G - RICHTECH ROBOTICS INC. (0001963685) (Subject)
SC 13G - Hepion Pharmaceuticals, Inc. (0001583771) (Subject)
SC 13G/A - Hepion Pharmaceuticals, Inc. (0001583771) (Subject)
4 - MIRA PHARMACEUTICALS, INC. (0001904286) (Issuer)
4 - MIRA PHARMACEUTICALS, INC. (0001904286) (Issuer)
4 - MIRA PHARMACEUTICALS, INC. (0001904286) (Issuer)
Cantor Fitzgerald initiated coverage of Hepion Pharmaceuticals with a rating of Overweight and set a new price target of $3.50
8-K - MIRA PHARMACEUTICALS, INC. (0001904286) (Filer)
8-K - MIRA PHARMACEUTICALS, INC. (0001904286) (Filer)
8-K - RICHTECH ROBOTICS INC. (0001963685) (Filer)
4 - MIRA PHARMACEUTICALS, INC. (0001904286) (Issuer)
4 - Hepion Pharmaceuticals, Inc. (0001583771) (Issuer)
4 - Hepion Pharmaceuticals, Inc. (0001583771) (Issuer)
- Demonstrated improvements among best reported of fibrosis-reducing compounds - - Liver stiffness results complemented by positive changes in disease biomarkers and HepQuant Duo liver function test - "These findings presented today at AASLD The Liver Meeting® confirm that rencofilstat's novel mechanism of action represents a fresh approach to the treatment of severe liver disease." (Patrick Mayo, PhD, Hepion's Senior VP, Clinical Pharmacology & Analytics) EDISON, N.J., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial Intelligence ("AI")-driven therapeutic drug development for the t
EDISON, N.J., Nov. 10, 2023 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial Intelligence ("AI")-driven therapeutic drug development for the treatment of non-alcoholic steatohepatitis ("NASH"), fibrotic diseases, hepatocellular carcinoma ("HCC"), and other chronic diseases, today announced that it expects to release additional efficacy data from the Phase 2 ALTITUDE-NASH clinical trial of its lead drug, rencofilstat, after market close on Monday, November 13, 2023. The data release will follow a late-breaker poster presentation by Hepion's Senior Vice President, Clinical Pharmacology, Patrick Mayo, PhD, at the
- Improvements in physiologic liver function and key NASH biomarkers including ALT, ProC3, PIIINP and ELF - - Results reinforce rencofilstat's direct antifibrotic mode of action; increases confidence for reductions in fibrosis in ongoing Phase 2b ‘ASCEND-NASH' paired biopsy trial - EDISON, N.J., May 22, 2023 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on artificial Intelligence ("AI")-assisted therapeutic drug development for the treatment of non-alcoholic steatohepatitis ("NASH"), fibrotic diseases, hepatocellular carcinoma ("HCC"), and other chronic diseases, today announced positive topline results from its recentl
Telomir Board of Directors appoints Erez Aminov as CEO and Chairman of the Board Telomir also announces Board of Directors departures and additions TAMPA, Fla., Aug. 12, 2024 (GLOBE NEWSWIRE) -- Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) ("Telomir" or the "Company"), a pre-clinical-stage pharmaceutical company focused on the development and commercialization of Telomir-1 to promote longevity in humans and dogs through the treatment of age-related conditions, today announced the passing of Chairman of the Board and Chief Executive Officer Christopher Chapman, Jr., M.D. Out of respect and privacy for Dr. Chapman's family, details of his passing will not be made available. Telomir's Boar
Richtech Robotics' AI service robot ADAM worked alongside Delaware North at Texas Rangers' Globe Life Field LAS VEGAS, July 23, 2024 (GLOBE NEWSWIRE) -- Richtech Robotics Inc. (NASDAQ:RR) ("Richtech Robotics"), a Nevada company and a provider of AI-driven service robots, today announces the official installation of their robotic solution ADAM at the Texas Rangers' Major League Baseball stadium, Globe Life Field. With unique AI capabilities and advanced human-like motions, ADAM will serve as the first humanoid bartender robot in any major league sports arena or large-scale entertainment venue. The launch of ADAM at Globe Life Field, in collaboration with global hospitality and entertainme
Ketamir-2, the Company's novel oral ketamine analog in development, aims to provide a safe and effective alternative for managing cancer pain and associated depression MIAMI, May 21, 2024 /PRNewswire/ -- MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) ("MIRA" or the "Company"), a pre-clinical-stage pharmaceutical company focused on the treatment of neurologic and neuropsychiatric disorders, announced it is in advanced discussions with Memorial Sloan Kettering Cancer Center (MSK) to initiate a preclinical study evaluating MIRA's novel oral ketamine analog, Ketamir-2, for the treatment of cancer-related pain and depression. MIRA Pharmaceuticals in Discussions with Memorial Sloan Kettering to Collabo